United Therapeutics (UTHR) Surges 10.7%: Is This an Indication of Further Gains?

Group 1 - United Therapeutics (UTHR) shares increased by 10.7% to close at $529.17, following a trading session with notable volume, contrasting with a 1.5% loss over the past four weeks [1] - The rise in shares is attributed to the announcement of a new $2 billion buyback program, which includes an initial $1.5 billion accelerated share repurchase agreement with Citibank, and up to $500 million available for additional repurchases at the company's discretion [2] - The company is expected to report quarterly earnings of $6.72 per share, reflecting a year-over-year increase of 1.4%, with revenues projected at $809.15 million, up 1.9% from the previous year [3] Group 2 - The consensus EPS estimate for United Therapeutics has been revised 4.1% lower over the last 30 days, indicating a negative trend in earnings estimate revisions, which typically does not lead to price appreciation [4] - United Therapeutics holds a Zacks Rank of 3 (Hold), while Korro Bio, Inc. (KRRO), another company in the same industry, closed 10% higher at $12.3 but has returned -11.1% over the past month [4] - Korro Bio, Inc. has an unchanged consensus EPS estimate of -$1.93 for the upcoming report, representing a 14.6% change from the previous year, and currently holds a Zacks Rank of 4 (Sell) [5]